Innovative genomic-based diagnostic technologies can help patients and healthcare professionals to assess risk and personalise treatment. Claire Takizawa and Juliette Plun-Favreau from Genomic Health explain why barriers to equal access should be urgently addressed
Prostate cancer …

Analysing several forms of immune modulation for prostate cancer and cases of early detection, Dr Arnulf Stenzl, Chairman, EberhardKarlsUniversity, explains why early treatment using a form of vaccination might treat the disease better
Prostate cancer is …

ExactVu™ micro-ultrasound offers a 300% improvement in resolution over conventional ultrasound, and is proving highly sensitive to prostate cancer, providing a powerful new tool to improve patient care
Prostate cancer is the most common cancer in …

Image Guided Adaptive Radiotherapy combines state of the art imaging and radiotherapy techniques. Dr Ben Pais, Vice President Medical Affairs, Elekta, says it will contribute to better, more efficient and cost-effective treatment of patients with …

By Prof Giuseppe Morgia, Urology Section, Department of Surgery, University of Catania
Prostate cancer (PCa) represents the most common cancer in men in developed countries in 2013. Incident cases increased more for prostate cancer than any …

By Chris Booth, Trustee, CHAPS Men’s Health Charity
Despite continuing controversy, (1) for the foreseeable future the blood test Prostate Specific Antigen (PSA) remains the only initial, simple, cheap option available to screen for Prostate Cancer …

Reducing over-diagnosis and the resulting overtreatment through refined and improved early detection is crucial in improving the quality of life and survival of prostate cancer patients. Dr Tit Albreht, Head of Centre, National Institute of …

Despite brachytherapy being highly effective among prostate cancer patients, availability of facilities differs across Europe and several countries are still under-equipped. Dr Bradley Pieters, Head – Brachytherapy Department, University of Amsterdam, calls for a uniform …

There have been several new promising therapies for prostate cancer, but many patients across Europe are not yet getting equal access to treatment. Dr Marisca Marian from Bayer calls on policy makers, researchers and key …

An increasing trend in the incidence of prostate cancer (PCa) has been observed in almost all European countries over the last few decades. There are no population-based, organised programmes for PCa in Europe as existing …